BRIEF-Galapagos reports start of FINCH Phase 3 program with filgotinib

* Reported on Monday the initiation of the FINCH global

Phase 3 program investigating the efficacy and safety of 100 mg

and 200 mg filgotinib once daily, in rheumatoid arthritis (RA)

patient populations, ranging from early stage to

biologic-experienced patients

Read more